CN112888687A - 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂 - Google Patents

三氟甲基取代的磺酰胺类选择性bcl-2抑制剂 Download PDF

Info

Publication number
CN112888687A
CN112888687A CN201980067260.1A CN201980067260A CN112888687A CN 112888687 A CN112888687 A CN 112888687A CN 201980067260 A CN201980067260 A CN 201980067260A CN 112888687 A CN112888687 A CN 112888687A
Authority
CN
China
Prior art keywords
compound
preparation
methyl
membered heterocycloalkyl
dmso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980067260.1A
Other languages
English (en)
Other versions
CN112888687B (zh
Inventor
刘飞
丰巍伟
王斌
徐宏江
汪纪楠
张喜全
王善春
刘彦龙
张健青
姚绎炎
唐旭静
施伟
张洪英
李洋
汤松
朱益忠
刘利民
顾红梅
杨玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202310104396.3A priority Critical patent/CN116199686A/zh
Publication of CN112888687A publication Critical patent/CN112888687A/zh
Application granted granted Critical
Publication of CN112888687B publication Critical patent/CN112888687B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

公开了包括三氟甲基取代的磺酰胺类选择性BCL‑2抑制剂，具体而言公开式I化合物、其立体异构体或其药学上可接受的盐、其制备方法以及该化合物的药物组合物，还公开了该化合物以及包含该化合物的药物组合物在治疗与抗凋亡蛋白BCL‑2相关疾病例如癌症中的用途。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980067260.1A 2018-10-29 2019-10-29 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂 Active CN112888687B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310104396.3A CN116199686A (zh) 2018-10-29 2019-10-29 三氟甲基取代的磺酰胺类化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2018112685722 2018-10-29
CN201811268572 2018-10-29
CN201910249783X 2019-03-29
CN201910249783 2019-03-29
CN2019109335130 2019-09-29
CN201910933513 2019-09-29
PCT/CN2019/113963 WO2020088442A1 (zh) 2018-10-29 2019-10-29 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310104396.3A Division CN116199686A (zh) 2018-10-29 2019-10-29 三氟甲基取代的磺酰胺类化合物

Publications (2)

Publication Number Publication Date
CN112888687A true CN112888687A (zh) 2021-06-01
CN112888687B CN112888687B (zh) 2023-01-24

Family

ID=70462524

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310104396.3A Pending CN116199686A (zh) 2018-10-29 2019-10-29 三氟甲基取代的磺酰胺类化合物
CN201980067260.1A Active CN112888687B (zh) 2018-10-29 2019-10-29 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310104396.3A Pending CN116199686A (zh) 2018-10-29 2019-10-29 三氟甲基取代的磺酰胺类化合物

Country Status (13)

Country Link
US (1) US20220002290A1 (zh)
EP (1) EP3858832A4 (zh)
JP (1) JP7473545B2 (zh)
KR (1) KR20210086680A (zh)
CN (2) CN116199686A (zh)
AU (1) AU2019372640B2 (zh)
BR (1) BR112021008323A2 (zh)
CA (1) CA3117849A1 (zh)
IL (1) IL282632B2 (zh)
MX (1) MX2021004856A (zh)
PH (1) PH12021550958A1 (zh)
SG (1) SG11202104322YA (zh)
WO (1) WO2020088442A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260191A (zh) * 2022-09-29 2022-11-01 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533740A (ja) * 2019-05-24 2022-07-25 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド メチル基及びトリフルオロメチル基を含む二置換スルファミド系選択的ｂｃｌ－２阻害剤
TW202144350A (zh) * 2020-04-29 2021-12-01 大陸商正大天晴藥業集團股份有限公司 三氟甲基和氯雙取代的磺醯胺類選擇性bcl-2抑制劑的晶體
WO2022161496A1 (en) * 2021-02-01 2022-08-04 Ascentage Pharma (Suzhou) Co., Ltd. Sulfonyl benzamide derivatives as bcl-2 inhibitors
WO2022253313A1 (zh) 2021-06-04 2022-12-08 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物的磷酸酯
WO2024012449A1 (zh) * 2022-07-12 2024-01-18 正大天晴药业集团股份有限公司 含有三氟甲基基团的化合物
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065824A2 (en) * 2008-12-04 2010-06-10 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102307872A (zh) * 2008-12-05 2012-01-04 雅培制药有限公司 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
CN104876927A (zh) * 2009-05-26 2015-09-02 艾伯维巴哈马有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402521B (zh) 2010-11-23 2016-01-20 艾伯维巴哈马有限公司 使用选择性的bcl-2抑制剂的治疗方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2018041248A1 (zh) 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065824A2 (en) * 2008-12-04 2010-06-10 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102307872A (zh) * 2008-12-05 2012-01-04 雅培制药有限公司 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
CN104876927A (zh) * 2009-05-26 2015-09-02 艾伯维巴哈马有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260191A (zh) * 2022-09-29 2022-11-01 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用

Also Published As

Publication number Publication date
CN116199686A (zh) 2023-06-02
CN112888687B (zh) 2023-01-24
AU2019372640A1 (en) 2021-06-03
IL282632A (en) 2021-06-30
CA3117849A1 (en) 2020-05-07
EP3858832A1 (en) 2021-08-04
BR112021008323A2 (pt) 2021-08-03
WO2020088442A1 (zh) 2020-05-07
JP7473545B2 (ja) 2024-04-23
SG11202104322YA (en) 2021-05-28
MX2021004856A (es) 2021-10-13
JP2022506442A (ja) 2022-01-17
AU2019372640B2 (en) 2022-08-04
US20220002290A1 (en) 2022-01-06
IL282632B1 (en) 2024-02-01
PH12021550958A1 (en) 2021-11-29
KR20210086680A (ko) 2021-07-08
IL282632B2 (en) 2024-06-01
EP3858832A4 (en) 2022-06-08

Similar Documents

Publication Publication Date Title
CN112888687A (zh) 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
CN113825754B (zh) 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂
CN111868059B (zh) 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
CA3008689A1 (en) Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
CN116761603A (zh) 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途
CN109641909A (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN108329274B (zh) 布鲁顿酪氨酸激酶抑制剂
CN110776511B (zh) 含喹啉环的btk抑制剂
CN116547276A (zh) 含酰胺基和杂环烷基的tyk2抑制剂化合物
CN114685532A (zh) 大环类化合物及其医药用途
RU2815486C9 (ru) Трифторметилзамещенный сульфонамид в качестве селективного ингибитора bcl-2
RU2815486C2 (ru) Трифторметилзамещенный сульфонамид в качестве селективного ингибитора bcl-2
CN114728943A (zh) 作为bcr-abl抑制剂的化合物
CN117377672A (zh) 三氟甲基取代的磺酰胺类化合物的磷酸酯
WO2023093812A1 (zh) 三氮唑酮类化合物的晶型及其应用
CN109206423B (zh) 作为RORγ抑制剂的硫代酰胺取代的二氢吡咯并吡啶化合物
CN115433179A (zh) 苯并嘧啶类化合物及其医药用途
CN117321064A (zh) 吉西他滨抗癌衍生物及抗癌医药用途
CN115894474A (zh) Rad51抑制剂化合物的晶型及其应用
CN115304605A (zh) 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用
KR20240090588A (ko) 피리딜 함유 화합물
CN115703764A (zh) 含三氮唑的核输出蛋白抑制剂
CN115925689A (zh) 含环丙基的核输出蛋白抑制剂
NZ755866A (en) Anti-fibrotic compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051476

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant